One in four people living with HIV in the United States are women. So why is HIV prevention medication overwhelmingly only targeted at men who have sex with men?
Between the high-tech sex toys, transplanted uteri, lab-grown penises, and perils of hookup apps, 2014 sometimes sounded like a science fiction novel. But we can’t forget the news about IUDs and STIs that came out this year, either.
Contrary to some initial reports, the World Health Organization did not declare that all men who have sex with men should start taking PrEP as a means of preventing HIV. Instead, the group wants this population to work with their health-care providers to assess their personal risk and determine whether PrEP is right for them.
This week, new research suggests that orgasms promote positive pillow talk and improve intimacy but alcohol has the opposite effect; a study finds that the new HIV-prevention drug Truvada may also reduce the risk of genital herpes; and a vibrator company introduced a Fitbit for your vagina.
PrEP works when used properly. So why don’t women use it?
In the months since the FDA’s approval of Truvada, some who work on prevention efforts in Black and low-income communities have urged PrEP proponents to pump their brakes.
A New York Times article looks at how parents do (and should) react when their children inevitably see Internet pornography, an FDA advisory panel recommends approving a drug for HIV-prevention, and Massachusetts cuts over $1 million from its HIV-prevention and testing program in county jails.
In this week’s sexual health roundup: scientists use engineered stem-cells to attack HIV; California tests a new pill that prevents HIV infection when taken daily but some question how expensive it is; the CDC releases alarming data on cancers caused by HPV in women; and South Carolina lawmakers take steps to increase HPV vaccination among middle school students.